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EPercutaneous Device Closure
of Patent Foramen Ovale for
Cryptogenic Strokes/Transient
Ischemic Attacks
We recently read with interest the recent meta-analysis performed by
Agarwal et al. (1) describing transcatheter closure versus medical therapy
for patent foramen ovale (PFO) in prevention of recurrent presumed
paradoxical embolism.We believe our study (2), which described 1 of the
largest series of PFO patients with presumed cryptogenic stroke or
transient ischemic attack (TIA) up to that date, meets their inclusion
criteria and should have been captured by their MEDLINE search. We
reported outcomes in 352 patients with presumed cryptogenic stroke/
TIA who underwent device closure of a PFO between December 2001
and June 2006. The mean follow-up duration was 37 months with a
maximum follow-up of 6 years (only 7 of 48 studies included in the
meta-analysis were followed for this duration or longer). Our subjects
underwent rigorous evaluation, including neurologic consultation,
brain imaging, thrombophilia screening, and cardiac arrhythmia
screens to exclude usual stroke causes before device closure.
The actuarial combined rate for recurrent stroke/TIA was 0.9% at
1 year and 2.8% at 4 years. Thrombophilia and elevated right heart
filling pressures were risk factors. There was no association between
the presence of residual shunt or atrial septal aneurysm and recurrent
events. There was no device thrombus detected in any patient.
After the inconclusive results of theCLOSURE1 (Safety andEfficacy
of the STARFlex Septal Closure System vs. Best Medical Therapy in
Patients with a Stroke or TIA due to Presumed Paradoxical Embolism
Through a PFO) trial (3), we also await the results of further randomized
ontrolled trials to provide us with evidence-based recommendations to
uide our management of patients with PFO and cryptogenic stroke/
IA. Until then, we continue to screen patients meticulously to rule out
sual causes of ischemic neurologic events and discuss with them the
imitations in our understanding of this common anatomic condition.
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Reply
We appreciate the interest expressed by Dr. Freund and colleagues in
our recent meta-analysis describing transcatheter closure versus med-
ical therapy for patent foramen ovale in prevention of recurrent
neurological events attributed to paradoxical thromboembolism (1).
e reviewed the study published by the authors in 2009 and agree
hat this study meets the criteria for inclusion in our meta-analysis and
hould have been included (2). The conclusions reached by the
uthors were very similar to those reported in our meta-analysis.
The study in question represents a well-characterized cohort of
atients who had a relatively long follow-up. We analyzed our data
gain after, including this study, and report that there were no
ignificant changes in the results and conclusions reached in our
tudy. The pooled incidence rate of recurrent neurological events
as calculated as 0.78%/year as compared with 0.76%/year re-
orted in our original meta-analysis. This difference is not statis-
ically significant. Besides this, the other subgroup analyses re-
orted in our original manuscript, including the impact of residual
hunting on recurrent events, remains unchanged.
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